Clinical trials: Pandemic
Healthy
Evaluating Technologies for Point-of-Care Blood Collections by Patients
A study evaluating technologies for point-of-care use in clinical trials.
- Trial name
- NCT06507566
- Testing
- Tasso+™
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years
The purpose of this study is to show that vaccination with a single dose of GSK Biologicals' pandemic H1N1 vaccine results in an immune response that meets or exceeds European Medicines Agency (EMEA) Committee for Medicinal…
- Trial name
- NCT01035749
- Testing
- GSK Biologicals' Influenza investigational vaccine GSK2340274A, GSK Biologicals' Influenza investigational vaccine GSK2340273A
- Where
- 9 sites in Estonia, Slovakia
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
- Trial name
- NCT00742885
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects
Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine
Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.
- Trial name
- NCT00562237
- Testing
- S205 10ugHA, S205 30ugHA, S205 10ugHA+500ugAlOH
- Where
- 6 sites in Finland, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
Influenza, Orthomyxoviridae Infections
Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults
The trial is a Phase II, open-label trial in healthy subjects aged 18 to 60 years to support the immunogenicity data from previous clinical studies. Objectives: To describe the immune response 21 days after each vaccination.
- Trial name
- NCT00545701
- Testing
- A/H5N1 inactivated, split-virion influenza virus
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Longitudinal Studies, Prospective Studies
Clinical Time and Temporal Dynamics Study (CLIN-TIME)
TH-CLINICAL-TIME is a prospective, longitudinal observational study evaluating how changes in clinical measurements over time may help researchers better understand patient health trajectories and clinically meaningful outcomes.
- Conditions
- Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests
- Trial name
- CLIN-TIME (NCT07812831)
- Testing
- No Study-Assigned Intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
COVID-19 Pandemic
SARS-CoV-2 OTC At Home Test
The objective of this study is to evaluate the 3EO Health COVID-19 Test in individuals presenting at a medical facility. In eligible subjects, nasal samples will be collected for use with the 3EO Health COVID-19 Test, which will…
- Trial name
- NCT05553964
- Testing
- In Vitro
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 3EO Health
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00694213
- Testing
- VCL-IPM1, VCL-IPT1, PBS
- Where
- 3 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vical
COVID-19 Pandemic
A Study of FB2001 for Inhalation in Healthy Chinese Adults
FB2001 is a novel inhalable preparation being developed for COVID-19 treatment. A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and…
- Trial name
- NCT05583812
- Testing
- FB2001 for inhalation
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
Pandemic Influenza Immunization, Healthy Volunteers
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against…
- Trial name
- NCT06907511
- Testing
- Pandemic flu H5 HA mRNA SD2 vaccine
- Where
- 13 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objective of this study is to assess the safety and immunogenicity of 4 different doses of adjuvanted and non-adjuvanted mock-up pandemic influenza vaccine.
- Trial name
- NCT00349141
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
- Where
- 3 sites in Austria, Singapore
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Human, Influenza in Birds
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
This is a Phase 2, randomized, multi-center study in approximately 300 adults who received 2 doses of aH5N1c or placebo in and completed the parent study V89_18 in the <65 years of age cohort.
- Conditions
- Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections
- Trial name
- NCT05422326
- Testing
- aH5N6c on Day 1, aH5N6c on Day 22
- Where
- 18 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Seqirus
Coronavirus, Respiratory Infection
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from…
- Conditions
- Coronavirus, Respiratory Infection, COVID
- Trial name
- NCT07221097
- Testing
- Investigational IVD for coronaviruses
- Where
- 6 sites in United States
- Volunteers
- 2,091 people
- Sponsor
- BioFire Defense LLC